Second-line epidermal growth factor receptor inhibitors followed by third-line pemetrexed or the reverse sequence: A retrospective analysis of 83 Chinese patients with advanced lung adenocarcinoma

Journal of Cancer Research and Clinical Oncology

Volumn 138, Issue 2, 2012, Pages 285-291

  Hong, Tingting ^a   Zhang, Ruxia ^a   Cai, Dongyan ^a   Wu, Xiaohong ^a   Hua, Dong ^a  

^a Soochow University   (China)

Author keywords

Epidermal growth factor receptor inhibitors; Lung adenocarcinoma; Pemetrexed; Treatment sequence

Indexed keywords

CISPLATIN; ERLOTINIB; GEFITINIB; GEMCITABINE; NAVELBINE; PEMETREXED;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER LOCALIZATION; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CHINESE; CONTROLLED STUDY; DRUG TREATMENT FAILURE; FEMALE; HUMAN; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; TREATMENT PLANNING; TREATMENT RESPONSE;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASIAN CONTINENTAL ANCESTRY GROUP; COHORT STUDIES; DISEASE-FREE SURVIVAL; FEMALE; GLUTAMATES; GUANINE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; NEOPLASM STAGING; PROGNOSIS; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 84857051374     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-011-1084-z     Document Type: Article

References (17)

1. Ciuleanu T, Brodowicz T, Zielinski C et al (2009) Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet 374: 1432-1440
2. Gridelli C, Butts C, Ciardiello F et al (2008) An international, multicenter, randomized phase III study of Wrst-line erlotinib followed by second-line cisplatin/gemcitabine versus Wrst-line cisplatin/ gemcitabine followed by second-line erlotinib in advanced nonsmall- cell lung cancer: treatment rationale and protocol dynamics of the TORCH trial. Clin Lung Cancer 9: 235-238
3. Hanna N, Shepherd FA, Fossella FV et al (2004) Randomized phase III trial of pemetrexed versus docetaxel in patients with non-smallcell lung cancer previously treated with chemotherapy. J Clin Oncol 22: 1589-1597 (Pubitemid 41079796)
4. Huang SF, Liu HP, Li LH et al (2004) High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to geWtinib responsiveness in Taiwan. Clin Cancer Res 10: 8195-8203
5. Kim ES, Hirsh V, Mok T et al (2008) GeWtinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): arandomised phase III trial. Lancet 372: 1809-1818
6. Maemondo M, Inoue A, Kobayashi K et al (2010) GeWtinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 362: 2380-2388
7. Miller VA, Kris MG, Shah N et al (2004) Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to geWtinib in advanced non-small-cell lung cancer. J Clin Oncol 22: 1103-1109 (Pubitemid 41095044)
8. Miller KD, Chap LI, Holmes FA et al (2005) Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 23: 792-799 (Pubitemid 46224178)
9. Mok TS, Wu YL, Thongprasert S et al (2009) GeWtinib or carboplatinpaclitaxel in pulmonary adenocarcinoma. N Engl J Med 361: 947-957
10. Pao W, Miller V, Zakowski M et al (2004) EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to geWtinib and erlotinib. Proc Natl Acad Sci USA 101: 13306-13311 (Pubitemid 39209661)
11. Scagliotti GV, Parikh P, von Pawel J et al (2008) Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-smallcell lung cancer. J Clin Oncol 26: 3543-3551
12. Schulz KF, Grimes DA (2005) Multiplicity in randomised trials II: subgroup and interim analyses. Lancet 365: 1657-1661 (Pubitemid 40693416)
13. Shepherd FA, Rodrigues Pereira J, Ciuleanu T et al (2005) Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353: 123-132 (Pubitemid 41058344)
14. Shigematsu H, Lin L, Takahashi T et al (2005) Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 97: 339-346 (Pubitemid 40425952)
15. Thatcher N, Chang A, Parikh P et al (2005) GeWtinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebocontrolled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 366: 1527-1537 (Pubitemid 41540110)
16. Tiseo M, Gridelli C, Cascinu S et al (2009) An expanded access program of erlotinib (Tarceva) in patients with advanced non-small cell lung cancer (NSCLC): data report from Italy. Lung Cancer 64: 199-206
17. Tsao MS, Sakurada A, Cutz JC et al (2005) Erlotinib in lung cancer- molecular and clinical predictors of outcome. N Engl J Med 353: 133-144 (Pubitemid 41058345)